publication . Article . 1995

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

S. Broder; James M. Pluda; I. Feuerstein; J. Odom; E. Feigel; Yarchoan R; R. W. Humphrey; M W Saville; Wyndham H. Wilson; Seth M. Steinberg; ...
Open Access
  • Published: 01 Jul 1995
Abstract We investigated whether paclitaxel was active in AIDS-associated Kaposi's sarcoma. We gave 135 mg/m 2 intravenously over 3 hours every 21 days. Follow-up is available on the first 20 patients, most of whom had advanced Kaposi's sarcoma and severe immuno-compromise. Neutropenia was the most frequent dose-limiting toxic effect; novel toxic effects included late fevers, rash, and eosinophilia. Creatinine increased in 2 patients and 1 patient had cardiomyopathy. There were 13 partial responses (65%, 95% Cl 41-85%). All 5 patients with pulmonary involvement responded. Paclitaxel appears to be active against Kaposi's sarcoma as a single agent. Further studies...
free text keywords: General Medicine, Gastroenterology, medicine.medical_specialty, medicine, Rash, medicine.symptom, Kaposi's sarcoma, medicine.disease, Chemotherapy, medicine.medical_treatment, Eosinophilia, Sarcoma, Immunology, Immunopathology, Internal medicine, Paclitaxel, chemistry.chemical_compound, chemistry, Neutropenia, business.industry, business
Related Organizations
Download fromView all 2 versions
Article . 1995
Provider: ZENODO
The Lancet
Provider: UnpayWall
The Lancet
Article . 2003
Provider: Crossref
Any information missing or wrong?Report an Issue